Survodutide: what it is and where it currently stands

If you have heard of survodutide, it is probably because of the buzz around the new generation of obesity drugs. Let's be clear from the outset: survodutide is not authorised or marketed in Spain. It does not appear in the AEMPS CIMA database and there is no summary of product characteristics for it, because it is an investigational compound whose safety and efficacy have not yet been approved by any regulatory authority. That said, there is plenty to explain about what it is, how it works and what its trials have shown, because the published information is solid and deserves to be told properly.

What survodutide is

Survodutide is a 29 amino acid peptide based on the glucagon molecule, with positions modified towards GLP-1 and exendin-4 (American Diabetes Association, abstract 1974-LB, 2025). Its distinctive feature is that it acts as a dual co-agonist: it activates both the GLP-1 receptor and the glucagon receptor (GCGR) at the same time. It is given subcutaneously once a week. Its development code is BI 456906: it comes from Zealand Pharma, which licensed it to Boehringer Ingelheim, the company responsible for its development.

To place it alongside more familiar names: semaglutide activates only the GLP-1 receptor, tirzepatide activates GLP-1 and GIP, and survodutide activates GLP-1 and glucagon (PMC12925197, 2025/2026). These are different mechanisms, which is why it is important not to assume that one is better than another: there are no direct head-to-head comparisons between survodutide and those drugs, and its data come from placebo-controlled trials: the phase 2 trials and, since 2026, the first phase 3 trial.

How it works

The thinking behind dual activation is to add together two effects via different routes. According to the peer-reviewed literature, survodutide reduces weight by combining two mechanisms: on the one hand, it increases energy expenditure through activation of the glucagon receptor in the liver; on the other, it reduces energy intake through GLP-1 receptor agonism in the brain (PMC12925197, 2025/2026). Put another way, the GLP-1 side is about eating less, and the glucagon side about burning a little more. It is a different approach from drugs that act on a single pathway.

What it showed in obesity

The phase 2 obesity trial was run across 43 centres in 12 countries. It included people aged 18 to 75 with a BMI of 27 kg/m² or above without diabetes, randomly assigned to five groups to receive weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (le Roux CW et al., Lancet Diabetes & Endocrinology 2024).

In the planned treatment analysis, weight reduction at 46 weeks was 14.9% with 4.8 mg, 13.2% with 3.6 mg, 12.5% with 2.4 mg, 6.2% with 0.6 mg and 2.8% with placebo. In addition, 55% of those receiving the 4.8 mg dose achieved weight loss of 15% or more. The most common adverse effects were gastrointestinal disorders, a familiar pattern with this family of drugs.

What it showed in liver disease (MASH)

MASH is steatohepatitis associated with metabolic dysfunction, a form of fatty liver disease with inflammation and damage that can progress to fibrosis. The phase 2 MASH trial lasted 48 weeks and included adults with biopsy-confirmed MASH and fibrosis stages F1 to F3, randomly assigned to receive weekly subcutaneous survodutide (2.4, 4.8 or 6.0 mg) or placebo, with a rapid 24-week dose escalation followed by a further 24 weeks of maintenance (Sanyal AJ et al., NEJM 2024).

Improvement in MASH without worsening of fibrosis was achieved in 47% of the 2.4 mg group, 62% of the 4.8 mg group and 43% of the 6.0 mg group, compared with 14% on placebo (P<0.001). In the subgroup with F2 and F3 fibrosis, up to 64.5% achieved improvement in fibrosis without worsening of MASH, compared with 25.9% (data presented at EASL 2024). The authors concluded that survodutide was superior to placebo for improvement in MASH without worsening of fibrosis, and that these results justify further investigation in phase 3.

Where it stands from a regulatory point of view

Survodutide is currently in phase 3 trials for obesity and for MASH, within the SYNCHRONIZE and LIVERAGE programmes, always with weekly dosing. The first phase 3 trial in obesity, SYNCHRONIZE-1, has now been published (New England Journal of Medicine, 2026): in 725 adults with obesity without diabetes, weight fell by 12.2% with 3.6 mg and by 13.0% with 6.0 mg at 76 weeks, compared with 5.4% with placebo, counting all participants even if they stopped treatment. It has received Fast Track and Breakthrough Therapy designations from the FDA for non-cirrhotic MASH with F2-F3 fibrosis, and has been accepted into the EMA's PRIME scheme for MASH with fibrosis.

It is worth understanding what those designations mean: they are mechanisms to speed up the development and review of a promising drug, but they are not the same as a marketing authorisation. Put simply, they speed up the journey; they do not finish it. That is why, as things stand today, survodutide remains an investigational compound.

In summary

Survodutide is an interesting molecule with solid phase 2 data in obesity and in liver disease, but it is still under investigation and cannot be used in Spain. What does exist in Spain today is medical weight-loss treatment, with prior assessment, a prescription where appropriate from a registered doctor and ongoing follow-up, so that decisions are made on sound grounds rather than on what you read online. If you want to know where to start, you can check whether you are eligible in a few minutes.